Juniper Pharmaceuticals Signs Definitive Agreement to be Acquired by Catalent, Inc. for $11.50 Per Share in Cash

BOSTON, July 3, 2018 -- (Healthcare Sales & Marketing Network) -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service contract development ... Biopharmaceuticals, Mergers & Acquisitions Juniper Pharmaceuticals, Catalent , CRINONE, progesterone gel
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news